GRAIL, Inc.

GRAIL, Inc. is a commercial-stage healthcare company dedicated to early cancer detection at population scale, primarily through its multi-cancer early detection (MCED) test, Galleri. The company's core mission is to detect cancer early, when it is more amenable to curative treatment, addressing the significant public health crisis where over 70% of cancer deaths result from cancers without recommended screening guidelines. GRAIL estimates that adding Galleri to the five standard-of-care single-cancer screening tests (breast, cervical, colorectal, lung, and prostate) has the potential to avert approximately 100,000 deaths per year in the United States, as measured by five-year survival, or 39% of expected five-year deaths if not for early detection by Galleri ¹. Additionally, early cancer diagnosis could result in $26 billion in annual cost-savings in the United States ². The company's business model revolves around generating revenue from sales of Galleri, which is currently offered as a laboratory developed test (LDT) in the United States, and from its precision oncology portfolio, which includes a research use only (RUO) targeted methylation platform. Primary customer segments for Galleri include healthcare systems, employers, digital health platforms, payors, and life insurance providers.

Galleri is GRAIL's flagship product, a multi-cancer early detection test that screens for over 50 types of cancer, with over 45 of these lacking recommended screening guidelines, from a simple blood draw. The test accurately predicts the Cancer Signal of Origin (CSO) with high positive predictive values (PPV) and low false positive rates. The company has conducted an extensive clinical program with data from over 385,000 participants ³, including the PATHFINDER 2 and NHS-Galleri Trials, which demonstrate clinical validation and utility. The precision oncology portfolio, launched in 2023, offers an RUO targeted methylation platform with customizable classifiers for applications such as disease prognostication, minimal residual disease (MRD) detection, and recurrence monitoring. This portfolio is supported by partnerships with oncology therapeutics companies, including AstraZeneca.

For the fiscal year ended December 31, 2025, GRAIL reported a net loss of $408.4 million ⁴. The company's accumulated deficit as of December 31, 2025, stood at $10.2 billion ⁵, with intangible assets of $1.9 billion ⁶. Cash and cash equivalents were $249.7 million ⁷, and short-term marketable securities were $654.7 million ⁸. The filing does not provide specific figures for total revenue, gross profit, gross margin, operating income, operating margin, basic and diluted EPS, free cash flow, total debt, or net debt for the reported fiscal period.

In terms of year-over-year comparisons, the filing indicates that sales of Galleri accounted for a substantial majority of revenue to date, with more than 475,000 commercial tests sold as of December 31, 2025, including over 185,000 tests in 2025 ⁹. This represents a significant increase in test volume compared to prior periods, though specific revenue growth rates by segment or margin expansion/contraction figures are not provided. The net loss for 2025 of $408.4 million ⁴ compares to a net loss of $2.0 billion for 2024 ¹⁰ and $1.5 billion for 2023 ¹¹, indicating a substantial reduction in net losses in 2025. Intangible asset impairments were $28.0 million for 2025 ¹², $1.4 billion for 2024 ¹³, and $0.7 billion for 2023 ¹⁴.

Significant operational developments during the period include the submission of a Pre-Market Approval (PMA) application to the FDA in January 2026 for Galleri ¹⁵, which includes data from the NHS-Galleri Prevalent Screening Round Results, PATHFINDER 2 Initial Results, and a bridging study. The company also announced topline results from the NHS-Galleri Trial in February 2026, which showed a substantial reduction in stage 4 cancer diagnoses (greater than 20% reduction in the second and third screening rounds) ¹⁶, increased stage 1 and 2 detection of deadly cancers, and a four-fold higher cancer detection rate when compared to recommended screenings alone ¹⁷. However, the trial did not meet its primary endpoint of statistically significant combined stage 3 and 4 reduction ¹⁸. In late 2024, GRAIL deployed an updated commercial version of Galleri incorporating an automated platform to scale more efficiently ¹⁹. The company also expanded internationally, launching Galleri in Israel in December 2024 ²⁰ and Canada in October 2025 ²¹, and announced a partnership with Samsung C&T to commercialize Galleri in South Korea, with a possible extension into other Asian geographies ²². A restructuring plan was approved by the Board of Directors to reprioritize resources on the core MCED business and reduce overall spend ²³.

Management's specific revenue, margin, or EPS guidance for the upcoming period is not explicitly stated in the filing. However, the company anticipates that it will continue to incur net losses for the coming years ²⁴.

A major growth area for GRAIL is the establishment of Galleri as the population multi-cancer screening standard and extending commercial leadership in large global markets. The commercial opportunity for Galleri is significant, with more than 300 million individuals globally over the age of 50 ²⁵, including over 100 million individuals in the United States ²⁶. The company aims to address cancer screening globally, starting with the United States and the United Kingdom, and expanding to other markets through direct entry and distributors. The company plans to continue engaging with key opinion leaders, healthcare providers, advocacy organizations, regulators, and payors to drive broader scientific and commercial endorsement worldwide. The NHS-Galleri Trial results, despite not meeting the primary endpoint, demonstrated a substantial reduction in stage 4 cancer diagnoses (greater than 20% reduction in the second and third screening rounds) ¹⁶, increased stage 1 and 2 detection of deadly cancers, and a four-fold higher cancer detection rate when compared to recommended screenings alone ¹⁷, which management believes will influence provider willingness to prescribe.

Another key growth vector is expanding access to products by pursuing FDA approval and reimbursement and coverage from payors. GRAIL submitted its PMA to the FDA in January 2026 ¹⁵, believing that FDA approval could unlock broad coverage by large commercial payors in the United States. In February 2026, the Nancy Gardner Sewell Medicare MCED Coverage Act became law, creating a Medicare coverage benefit category for MCED tests, with authority for CMS to initiate coverage as early as January 1, 2029, for those aged 50-65, expanding by one age-year annually ²⁷. The company also expects to pursue inclusion of Galleri in the USPSTF's guideline recommendation if FDA approval is obtained, although this is not certain and may take several years ²⁸. In the United Kingdom, NHS England will evaluate the final results from the NHS-Galleri Trial before deciding on implementation, with final results expected in mid-2026 ²⁹. The company believes its work with the NHS and the data from the NHS-Galleri Trial could facilitate adoption in other single-payor systems globally.

Regarding operational outlook, GRAIL expects to leverage the scale efficiencies of its infrastructure and platform technology, which it believes will positively impact margins over time ³⁰. The company has made significant investments to build a scalable infrastructure capable of meeting demand of up to one million tests per year ³¹ at its Durham, North Carolina facility, which operates 16 hours a day, seven days a week ³². The updated commercial version of Galleri, deployed in late 2024, incorporates significant automation to enable more efficient scaling with future demand ¹⁹. The company continually monitors and evaluates laboratory operations and performance to achieve intended sample processing metrics and costs.

Planned capital allocation includes continued investment in clinical evidence generation and working with regulatory bodies and payors in target markets to expand coverage for early cancer screening and increase access ³³. The company also plans to continue driving cutting-edge science and technology to continuously improve existing products and develop new ones, leveraging its methylation platform and extensive technological infrastructure ³⁴. This includes further refining and selecting subsets of highly informative regions for CSO detection to reduce panel size, achieve deeper sequencing coverage, and lower sequencing costs, as demonstrated with the new version launched in 2024 ³⁵. The company also aims to improve test sensitivity by obtaining deeper sequencing coverage and a better understanding of noise, and by leveraging larger datasets to develop advanced machine learning algorithms ³⁶.

Structural headwinds and execution risks management explicitly flagged include the NHS-Galleri Trial not meeting its primary endpoint of statistically significant combined Stage 3 and 4 reduction, which may negatively impact perceptions of Galleri's clinical utility among healthcare providers, payors, regulators, potential commercial partners, and the investment community ³⁷. This could adversely affect the ability to obtain coverage and reimbursement, secure implementation in the NHS, achieve broad commercial adoption, or enter into partnerships on favorable terms. Another risk is that no version of Galleri has been approved or cleared by the FDA, and obtaining PMA approval can take several years, if at all, from the time of submission ³⁸. The company also faces risks related to its reliance on Illumina as a sole supplier for next-generation sequencers and associated reagents, Madison Industries for blood collection tubes, and Twist Bioscience Corporation for DNA panels ³⁹. The perpetual 9% royalty payment obligation to Illumina on net sales generated by products or revenues in the field of oncology, subject to certain reductions and a floor of 7% ⁴⁰, will resume after December 24, 2026, or an earlier change of control ⁴¹, which could impact gross margins.

Geographic, regulatory, or macro factors identified as constraints include the uncertainty surrounding FDA regulation of laboratory developed tests (LDTs) following the vacating of the LDT Final Rule by a federal court in March 2025 and its subsequent rescission by the FDA in September 2025 ⁴². This uncertainty could affect the FDA's ability to apply and enforce medical device authority with respect to LDTs, including those for which a PMA is sought. The regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable ⁴³. The EU IVDR, which became effective on May 26, 2022, imposes a new regulatory framework for IVDs in the EU, with Galleri benefiting from a grace period until December 31, 2028, for full compliance as a Class C IVD ⁴⁴. The UK also has evolving regulations for IVDs following Brexit, with new legislation on pre-market requirements expected in 2026 ⁴⁵. Geopolitical conflicts have impacted recent sales in Israel ⁴⁶.

GRAIL operates in a rapidly evolving field with a limited operating history and has incurred significant net losses, including $408.4 million in 2025 ⁴, and anticipates continued losses. The NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction ¹⁸, which may negatively impact perceptions of Galleri's clinical utility among healthcare providers, payors, regulators, and the investment community, potentially hindering regulatory approvals, coverage, and commercial adoption. The company is highly dependent on Galleri sales for revenue and its commercial success is contingent on adequate coverage and reimbursement from third-party payors, which is uncertain, particularly with Medicare coverage for MCED tests only authorized to begin as early as January 1, 2029, for those aged 50-65, expanding annually ²⁷. GRAIL relies on sole suppliers for critical components, including Illumina for sequencers and reagents, Madison Industries for blood collection tubes, and Twist Bioscience Corporation for DNA panels ³⁹, creating supply chain vulnerabilities. The perpetual 9% royalty to Illumina on oncology net sales, subject to a 7% floor ⁴⁰, will resume after December 24, 2026 ⁴¹, impacting future gross margins. The company's information technology systems are vulnerable to cybersecurity incidents, and any failure could lead to significant liabilities and reputational damage. The regulatory landscape for LDTs is uncertain following the vacating of the FDA's LDT Final Rule ⁴², and the lengthy and unpredictable FDA approval process for MCED tests, a novel approach to cancer screening, poses significant risks to commercialization. Furthermore, the evolving regulatory frameworks for AI Technologies in the EU and US could limit the company's ability to use AI, requiring costly compliance measures and potentially increasing civil claims.

Management's message to shareholders emphasizes the company's mission to detect cancer early to improve patient outcomes, highlighting the significant opportunity to reduce the global burden of cancer. They underscore the extensive clinical program, with data from over 385,000 participants ³, demonstrating the clinical validation and utility of Galleri. Despite the NHS-Galleri Trial not meeting its primary endpoint of statistically significant combined Stage 3 and 4 reduction ¹⁸, management points to favorable secondary endpoints, such as a substantial reduction in stage 4 cancer diagnoses (greater than 20% reduction in the second and third screening rounds) ¹⁶ and a four-fold higher cancer detection rate when compared to recommended screenings alone ¹⁷, as compelling evidence of clinical utility. The three strategic priorities emphasized for the period ahead are establishing Galleri as the population multi-cancer screening standard and extending commercial leadership in large global markets, expanding access to products by pursuing FDA approval and reimbursement and coverage from payors, and driving cutting-edge science and technology to continuously improve existing products and develop new ones. Management is confident that the PMA submission to the FDA in January 2026 ¹⁵ could unlock broad commercial payor coverage in the United States, and they are actively pursuing Medicare coverage under the new Nancy Gardner Sewell Medicare MCED Coverage Act, which authorizes coverage as early as January 1, 2029, for those aged 50-65 ²⁷.